Nektar Therapeutics (NASDAQ:NKTR) closed its last session at $19.11 with the change of +2.30%. The market capitalization of the company is $2.61B with an average Volume of 1.02 million shares. The stock currently has its 52-Week High range of $19.98 and 52-week low range of $9.92. The stock traded total quantity of 1.67 million shares.
Currently Nektar Therapeutics (NKTR) captured an average recommendation of “ Buy ” from analysts, according to FactSet data. The stock has been suggested as “Buy” from “7″ Analysts”. “0” rated “Sell” for the company. “0” said the company as a “Hold”. Overweight rating was given by “0” and Underweight rating was given by “0”.
Analysts are expecting that the company to achieve $20.17 Price Target in next 52-weeks, average price is come up through the consensus of analysts. High potential price target is set at $25.00 however minimum price target advised by analysts is $18.00. The Median price target for the stock is measured at $19.50.
Presently, Analysts decided consensus EPS estimate of $-0.34 for present quarter and one month ago projected EPS estimate was at $-0.34. If we take a look at back 3 month ago, consensus EPS estimate was $-0.30.
A current consensus EPS estimate for next quarter is at $-0.28 and 3 month ago EPS forecast was $-0.22. Have a look at back 1 month ago, consensus EPS forecast was seen at $-0.28.
For current fiscal year, most recent EPS estimate is set at $-1.07 based on Analyst consensus and three month ago consensus EPS opinions was at $-0.95. During period one month ago, consensus EPS forecast was decided at $-1.07.
A current consensus EPS projection for next fiscal year is observed at $-0.94 and one month ago consensus EPS forecast was at $-0.94. Take a look at back three month ago, consensus EPS estimate opinions was decided at $-0.71 by analysts.
One Month ago, the stock has gained consensus mean rating of Buy based on the analysis of brokerage analyst firms polled. 7 presented the recommendations about the stock as a “Buy” signal and “Overweight” signal was reported by 0. 0 advised the “Hold” rating about this stock. 0 revealed “Sell” signal and “Underweight” rating was declared by 0.
Three Months Ago, Analysts recommended an average brokerage rating of Buy derived from brokerage firms, according to FactSet. 8 said a “Buy Rating” and 0 announced “Overweight Rating”. 0 advised “Hold Rating” regarding the stock. 0 announced “Sell Rating” and 0 disclosed “Underweight Rating”.